Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Key Highlights
- ➤Valion Bio (VBIO) sets 30-day agenda focused on pipeline, revenue, and strategic flexibility
- ➤Entolimod has received approximately $35.6 million in non-dilutive government funding
- ➤AFRRI evaluates Entolimod for radiation-induced gastrointestinal injury under Department of War funding
- ➤Valion pursues Entolimod trial with Sheba Medical Center in high-dose radiation cancer patients
- ➤Velocity Bioworks strategic review may include partnerships, licensing, co-investment, joint ventures, or sale
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Having served on Valion’s Board of Directors for more than seven years, I have a deep understanding of the Company’s science, assets, and people, and I believe those factors provide a meaningful foundation for future success.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“It is also clear to me there has been a significant and persistent gap between these and how the stock market has seen and valued our Company.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“My initial review has reinforced the importance of translating our underlying strengths into measurable development progress, commercial traction, and disciplined capital allocation.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Our focus is on advancing the opportunities with the greatest potential to create value for shareholders, while remaining pragmatic about how we fund, develop, and commercialize our assets.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Entolimod has benefited from substantial government support, human safety experience, and continued interest in its potential applications in radiation injury.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We are evaluating how to build on that foundation through ongoing research, additional development pathways, and formulation innovation.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“An oral mucosal formulation, if successfully developed and validated, could offer a differentiated administration option with potential relevance to emergency preparedness and other settings where rapid, scalable deployment may be important.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Velocity is an important part of Valion’s opportunity to translate technical capabilities into commercial value.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We are actively pursuing new customers and evaluating opportunities to expand the CDMO’s reach.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Our priority is to build commercial momentum around the capabilities we have, while determining how best to position Velocity for sustainable growth and greater strategic value.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Commercial execution and strategic flexibility are not mutually exclusive.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We are pursuing customer and licensing opportunities while evaluating the full range of strategic options available to us, whether continued development within Valion, a strategic partnership, co-investment, or another structure that creates value for shareholders.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Our responsibility is to translate Valion’s assets and capabilities into tangible progress.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“That means advancing our science, pursuing commercial opportunities with discipline, and remaining open to the strategic structures that can best support our objectives.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We intend to approach these priorities with urgency, accountability, and a clear focus on long-term value creation.”
SAN ANTONIO, TX / ACCESS Newswire / October 21, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today shared the initial findings and priorities from Dean Zikria's first 30 days as Interim Chief Executive Officer. Mr. Zikria's strategic review has set a focused agenda built on three priorities: * Advancing the development of Entolimod and other pipeline assets; * Pursuing customer and revenue capabilities for Velocity Bioworks ("Velocity"), the Company's wholly owned contract development and manufacturing organization ("CDMO"); and * Evaluating strategic partnerships, co-investment structures, licensing deals, and/or other transactions for Velocity that could unlock additional value from the CDMO. "Having served on Valion's Board of Directors for more than seven years, I have a deep understanding of the Company's science, assets, and people, and I believe those factors provide a meaningful foundation for future success," said Mr. Zikria. "It is also clear to me there has been a significant and persistent gap between these and how the stock market has seen and valued our Company. My initial review has reinforced the importance of translating our underlying strengths into measurable development progress, commercial traction, and disciplined capital allocation. Our focus is on advancing the opportunities with the greatest potential to create value for shareholders, while remaining pragmatic about how we fund, develop, and commercialize our assets."
Get started
Create a free account to read the full story.